Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02833467Unknown

Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA

Role: collaborator

NCT02696525Unknown

Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients

Role: collaborator

NCT02907606Unknown

Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study

Role: collaborator

All 3 trials loaded